Metronidazole (Flagyl), misonidazole (Ro 07-0582), iron, zinc and sulphur compounds in cancer therapy

Research output: Contribution to journalArticleResearchpeer review

Authors

  • D. Bahnemann
  • H. Basaga
  • J. R. Dunlop
  • A. J. Searle
  • R. L. Willson

Research Organisations

View graph of relations

Details

Original languageEnglish
Pages (from-to)16-19
Number of pages4
JournalBritish Journal of Cancer
Volume37
Issue numberSUPPL.3
Publication statusPublished - 1978

Abstract

The nitro radiosensitizers, metronidazole and misonidazole, have been shown to react rapidly with the sulphydryl compounds cysteine and cysteamine in the presence of ferrous ions. Similar reactions occur in the presence of copper ions but these are much slower. The initial interactions of the drugs and of oxygen with an iron-cysteine complex are extremely rapid: in the case of oxygen reaction half lives of 27 ms have been measured. Misonidazole also reacts rapidly with glutathione in the presence of ferrous ions and is subsequently reduced: metronidazole is reduced only slowly if at all. These reactions, which have been found to be inhibited by high concentrations of zinc ions, are discussed in the light of the known radiosensitizing and chemotherapeutic efficiencies of the nitro drugs and the side effect of peripheral neuropathy sometimes observed during their clinical use.

ASJC Scopus subject areas

Sustainable Development Goals

Cite this

Metronidazole (Flagyl), misonidazole (Ro 07-0582), iron, zinc and sulphur compounds in cancer therapy. / Bahnemann, D.; Basaga, H.; Dunlop, J. R. et al.
In: British Journal of Cancer, Vol. 37, No. SUPPL.3, 1978, p. 16-19.

Research output: Contribution to journalArticleResearchpeer review

Bahnemann, D, Basaga, H, Dunlop, JR, Searle, AJ & Willson, RL 1978, 'Metronidazole (Flagyl), misonidazole (Ro 07-0582), iron, zinc and sulphur compounds in cancer therapy', British Journal of Cancer, vol. 37, no. SUPPL.3, pp. 16-19.
Bahnemann, D., Basaga, H., Dunlop, J. R., Searle, A. J., & Willson, R. L. (1978). Metronidazole (Flagyl), misonidazole (Ro 07-0582), iron, zinc and sulphur compounds in cancer therapy. British Journal of Cancer, 37(SUPPL.3), 16-19.
Bahnemann D, Basaga H, Dunlop JR, Searle AJ, Willson RL. Metronidazole (Flagyl), misonidazole (Ro 07-0582), iron, zinc and sulphur compounds in cancer therapy. British Journal of Cancer. 1978;37(SUPPL.3):16-19.
Bahnemann, D. ; Basaga, H. ; Dunlop, J. R. et al. / Metronidazole (Flagyl), misonidazole (Ro 07-0582), iron, zinc and sulphur compounds in cancer therapy. In: British Journal of Cancer. 1978 ; Vol. 37, No. SUPPL.3. pp. 16-19.
Download
@article{f09e5c460c3d4672a88bf6edbcc0337e,
title = "Metronidazole (Flagyl), misonidazole (Ro 07-0582), iron, zinc and sulphur compounds in cancer therapy",
abstract = "The nitro radiosensitizers, metronidazole and misonidazole, have been shown to react rapidly with the sulphydryl compounds cysteine and cysteamine in the presence of ferrous ions. Similar reactions occur in the presence of copper ions but these are much slower. The initial interactions of the drugs and of oxygen with an iron-cysteine complex are extremely rapid: in the case of oxygen reaction half lives of 27 ms have been measured. Misonidazole also reacts rapidly with glutathione in the presence of ferrous ions and is subsequently reduced: metronidazole is reduced only slowly if at all. These reactions, which have been found to be inhibited by high concentrations of zinc ions, are discussed in the light of the known radiosensitizing and chemotherapeutic efficiencies of the nitro drugs and the side effect of peripheral neuropathy sometimes observed during their clinical use.",
author = "D. Bahnemann and H. Basaga and Dunlop, {J. R.} and Searle, {A. J.} and Willson, {R. L.}",
note = "Copyright: Copyright 2012 Elsevier B.V., All rights reserved.",
year = "1978",
language = "English",
volume = "37",
pages = "16--19",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "SUPPL.3",

}

Download

TY - JOUR

T1 - Metronidazole (Flagyl), misonidazole (Ro 07-0582), iron, zinc and sulphur compounds in cancer therapy

AU - Bahnemann, D.

AU - Basaga, H.

AU - Dunlop, J. R.

AU - Searle, A. J.

AU - Willson, R. L.

N1 - Copyright: Copyright 2012 Elsevier B.V., All rights reserved.

PY - 1978

Y1 - 1978

N2 - The nitro radiosensitizers, metronidazole and misonidazole, have been shown to react rapidly with the sulphydryl compounds cysteine and cysteamine in the presence of ferrous ions. Similar reactions occur in the presence of copper ions but these are much slower. The initial interactions of the drugs and of oxygen with an iron-cysteine complex are extremely rapid: in the case of oxygen reaction half lives of 27 ms have been measured. Misonidazole also reacts rapidly with glutathione in the presence of ferrous ions and is subsequently reduced: metronidazole is reduced only slowly if at all. These reactions, which have been found to be inhibited by high concentrations of zinc ions, are discussed in the light of the known radiosensitizing and chemotherapeutic efficiencies of the nitro drugs and the side effect of peripheral neuropathy sometimes observed during their clinical use.

AB - The nitro radiosensitizers, metronidazole and misonidazole, have been shown to react rapidly with the sulphydryl compounds cysteine and cysteamine in the presence of ferrous ions. Similar reactions occur in the presence of copper ions but these are much slower. The initial interactions of the drugs and of oxygen with an iron-cysteine complex are extremely rapid: in the case of oxygen reaction half lives of 27 ms have been measured. Misonidazole also reacts rapidly with glutathione in the presence of ferrous ions and is subsequently reduced: metronidazole is reduced only slowly if at all. These reactions, which have been found to be inhibited by high concentrations of zinc ions, are discussed in the light of the known radiosensitizing and chemotherapeutic efficiencies of the nitro drugs and the side effect of peripheral neuropathy sometimes observed during their clinical use.

UR - http://www.scopus.com/inward/record.url?scp=0018144209&partnerID=8YFLogxK

M3 - Article

C2 - 277218

AN - SCOPUS:0018144209

VL - 37

SP - 16

EP - 19

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - SUPPL.3

ER -